TWI252761B - Sustained-release formulations for treating CNS-mediated disorders - Google Patents
Sustained-release formulations for treating CNS-mediated disorders Download PDFInfo
- Publication number
- TWI252761B TWI252761B TW090108635A TW90108635A TWI252761B TW I252761 B TWI252761 B TW I252761B TW 090108635 A TW090108635 A TW 090108635A TW 90108635 A TW90108635 A TW 90108635A TW I252761 B TWI252761 B TW I252761B
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutical composition
- acid
- compound
- active compound
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16021099P | 1999-10-19 | 1999-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI252761B true TWI252761B (en) | 2006-04-11 |
Family
ID=22575965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW090108635A TWI252761B (en) | 1999-10-19 | 2001-04-11 | Sustained-release formulations for treating CNS-mediated disorders |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1225888A2 (fr) |
JP (1) | JP2003512311A (fr) |
CN (1) | CN1409630A (fr) |
AU (1) | AU780505B2 (fr) |
CA (1) | CA2387819A1 (fr) |
MX (1) | MXPA02003976A (fr) |
TW (1) | TWI252761B (fr) |
WO (1) | WO2001028516A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6589994B1 (en) | 1996-08-30 | 2003-07-08 | Nps Pharmaceuticals, Inc. | Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound |
MY142204A (en) | 2002-07-25 | 2010-10-29 | Pharmacia Corp | Pramipexole once-daily dosage form |
WO2006012603A2 (fr) * | 2004-07-22 | 2006-02-02 | Nps Pharmaceuticals, Inc. | Analogues de l'isovaleramide, composition pharmaceutique contenant ces analogues et methode permettant de traiter des maladies ou des affections du systeme nerveux central |
CA2576386A1 (fr) | 2004-08-13 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Preparation d'une pastille a autorisation de sortie elargie, contenant du pramipexole ou un sel de pramipexole pharmaceutiquement acceptable, procede de fabrication et d'utilisation de cette pastille |
PL1789021T3 (pl) * | 2004-08-13 | 2012-04-30 | Boehringer Ingelheim Int | Preparat tabletkowy o przedłużonym uwalnianiu zawierający pramipeksol lub jego farmaceutycznie dopuszczalną sól |
US20070134315A1 (en) * | 2005-12-08 | 2007-06-14 | Viera Michael L | Orally administrable extended release pellet and tablet formulations of a highly water soluble compound |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL128724A (en) * | 1996-08-30 | 2003-05-29 | Nps Pharma Inc | Pharmaceutical compositions containing isovaleric acid derivatives for treating various neurological pathologies |
-
2000
- 2000-10-19 JP JP2001531111A patent/JP2003512311A/ja active Pending
- 2000-10-19 CN CN00817059A patent/CN1409630A/zh active Pending
- 2000-10-19 WO PCT/US2000/041267 patent/WO2001028516A2/fr active IP Right Grant
- 2000-10-19 AU AU19695/01A patent/AU780505B2/en not_active Ceased
- 2000-10-19 MX MXPA02003976A patent/MXPA02003976A/es active IP Right Grant
- 2000-10-19 CA CA002387819A patent/CA2387819A1/fr not_active Abandoned
- 2000-10-19 EP EP00982701A patent/EP1225888A2/fr not_active Withdrawn
-
2001
- 2001-04-11 TW TW090108635A patent/TWI252761B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2003512311A (ja) | 2003-04-02 |
MXPA02003976A (es) | 2003-09-25 |
AU1969501A (en) | 2001-04-30 |
CA2387819A1 (fr) | 2001-04-26 |
WO2001028516A3 (fr) | 2002-02-21 |
CN1409630A (zh) | 2003-04-09 |
AU780505B2 (en) | 2005-03-24 |
WO2001028516A2 (fr) | 2001-04-26 |
EP1225888A2 (fr) | 2002-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210113469A1 (en) | Sustained release compositions using wax-like materials | |
KR0140492B1 (ko) | 방출억제성 오피오이드 제형 | |
AU2005307052B2 (en) | Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane | |
ES2226886T3 (es) | Forma de administracion de accion retardada que contiene sacarinato de tramadol. | |
RU2548748C2 (ru) | Композиции, включающие слабоосновные лекарственные вещества, и лекарственные формы с контролированным высвобождением | |
JP5845173B2 (ja) | 非オピオイドおよびオピオイド鎮痛薬の組み合わせを含む口腔内崩壊錠組成物 | |
US20070259040A1 (en) | Novel triptan formulations and methods for making them | |
JP2007509155A (ja) | クエチアピンを含有する薬剤 | |
JP2008540437A (ja) | キニーネを含有する制御放出調合剤 | |
JP2010504950A (ja) | 医薬組成物 | |
CN109069480A (zh) | 用于治疗与癫痫相关的病症的方法和组合物 | |
JP2004521910A (ja) | トラマドール系薬剤 | |
JP2018520112A (ja) | 制御持続放出プレガバリン | |
CA2677076C (fr) | Compositions comprenant du carisoprodol, et leurs procedes d'utilisation | |
US20050163843A1 (en) | Alprazolam formulations | |
JPH06279274A (ja) | 懸濁液徐放性製薬組成物 | |
CA2841731A1 (fr) | Compositions de nicotinamide et leur utilisation therapeutique | |
TWI252761B (en) | Sustained-release formulations for treating CNS-mediated disorders | |
MX2008015357A (es) | Formulaciones de liberacion pulsada de fenilefrina y composiciones farmaceuticas. | |
US7235258B1 (en) | Sustained-release formulations for treating CNS-mediated disorders | |
RU2336863C2 (ru) | Препараты в виде пеллет сферической формы | |
EP1448173A2 (fr) | Procede de fabrication d'une composition pharmaceutique a liberation prolongee contenant des microbilles de trimetazidine dihydrochloride | |
JP2024507264A (ja) | メラトニンを含む多層ペレットの製剤 | |
AU2005202728A1 (en) | Sustained-release formulations for treating CNS-mediated disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |